These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 18443476)
1. Poly(ADP-ribose) polymerase: a new therapeutic target? Gerö D; Szabó C Curr Opin Anaesthesiol; 2008 Apr; 21(2):111-21. PubMed ID: 18443476 [TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases. Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586 [TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. Radovits T; Lin LN; Zotkina J; Gero D; Szabó C; Karck M; Szabó G Eur J Pharmacol; 2007 Jun; 564(1-3):158-66. PubMed ID: 17397824 [TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. Xiao CY; Chen M; Zsengellér Z; Li H; Kiss L; Kollai M; Szabó C J Pharmacol Exp Ther; 2005 Mar; 312(3):891-8. PubMed ID: 15523000 [TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Jagtap P; Szabó C Nat Rev Drug Discov; 2005 May; 4(5):421-40. PubMed ID: 15864271 [TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-Ribose) polymerase inhibition improves endothelial dysfunction induced by hypochlorite. Radovits T; Zotkina J; Lin LN; Bömicke T; Arif R; Gerö D; Horváth EM; Karck M; Szabó C; Szabó G Exp Biol Med (Maywood); 2007 Oct; 232(9):1204-12. PubMed ID: 17895528 [TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update. Horvath EM; Szabó C Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094 [TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications. Sodhi RK; Singh N; Jaggi AS Vascul Pharmacol; 2010; 53(3-4):77-87. PubMed ID: 20633699 [TBL] [Abstract][Full Text] [Related]
9. Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Soriano FG; Nogueira AC; Caldini EG; Lins MH; Teixeira AC; Cappi SB; Lotufo PA; Bernik MM; Zsengellér Z; Chen M; Szabó C Crit Care Med; 2006 Apr; 34(4):1073-9. PubMed ID: 16484919 [TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis. Kauppinen TM; Suh SW; Genain CP; Swanson RA J Neurosci Res; 2005 Jul; 81(2):190-8. PubMed ID: 15931673 [TBL] [Abstract][Full Text] [Related]
11. Toward specific functions of poly(ADP-ribose) polymerase-2. Yélamos J; Schreiber V; Dantzer F Trends Mol Med; 2008 Apr; 14(4):169-78. PubMed ID: 18353725 [TBL] [Abstract][Full Text] [Related]
12. Effect of tempol, a membrane-permeable radical scavenger, on mesenteric blood flow and organ injury in a murine cecal ligation and puncture model of septic shock. Yuksel BC; Serdar SE; Tuncel A; Uzum N; Ataoglu O; Atan A; Hengirmen S; Iskit AB; Guc MO Eur Surg Res; 2009; 43(2):219-27. PubMed ID: 19556798 [TBL] [Abstract][Full Text] [Related]
13. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Ratnam K; Low JA Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279 [TBL] [Abstract][Full Text] [Related]
14. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors. Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672 [TBL] [Abstract][Full Text] [Related]
15. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer. Lewis C; Low JA Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575 [TBL] [Abstract][Full Text] [Related]
16. Establishment of an immortalized PARP-1-/- murine endothelial cell line: a new tool to study PARP-1 mediated endothelial cell dysfunction. Carrillo A; Monreal Y; Ramirez P; Suarez E; Parrilla P; Menissier-de Murcia J; de Murcia G; Alvarez-Vallina L; Yélamos J J Cell Biochem; 2005 Apr; 94(6):1163-74. PubMed ID: 15696577 [TBL] [Abstract][Full Text] [Related]
17. Metformin suppresses high glucose-induced poly(adenosine diphosphate-ribose) polymerase overactivation in aortic endothelial cells. Mahrouf-Yorgov M; Marie N; Borderie D; Djelidi R; Bonnefont-Rousselot D; Legrand A; Beaudeux JL; Peynet J Metabolism; 2009 Apr; 58(4):525-33. PubMed ID: 19303974 [TBL] [Abstract][Full Text] [Related]
18. Effect of oxidative stress and involvement of poly(ADP-ribose) polymerase (PARP) in Dictyostelium discoideum development. Rajawat J; Vohra I; Mir HA; Gohel D; Begum R FEBS J; 2007 Nov; 274(21):5611-8. PubMed ID: 17922841 [TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) makes a date with death. Heeres JT; Hergenrother PJ Curr Opin Chem Biol; 2007 Dec; 11(6):644-53. PubMed ID: 17936669 [TBL] [Abstract][Full Text] [Related]